---
title: "Stakeholder views on introducing a novel tuberculosis vaccine for adolescents and adults in Pakist"
id: "medrxiv-5-stakeholder-perspectives-on-the-potential-introduction-of-a-novel-tuberculosis"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-5-stakeholder-perspectives-on-the-potential-introduction-of-a-novel-tuberculosis"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.08.26.26360963v1?rss=1"
published_at: "2026-08-31T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Stakeholder views on introducing a novel tuberculosis vaccine for adolescents and adults in Pakist
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-5-stakeholder-perspectives-on-the-potential-introduction-of-a-novel-tuberculosis
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.08.26.26360963v1?rss=1)
- **Published At:** 2026-08-31T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This qualitative study explored perspectives of ten key stakeholders in Pakistan on introducing a novel **tuberculosis (TB) vaccine** for adolescents and adults. - Stakeholders were drawn purposively from national and provincial TB programs, the Expanded Programme on Immunization (EPI), clinical settings, and academia. - Semi-structured in-depth interviews were conducted in English or Urdu, audio-recorded, transcribed verbatim, and analyzed using reflexive thematic analysis (Braun and Clarke framework) with hybrid deductive-inductive coding. - Participants strongly supported introduction of a new **TB vaccine** because of Pakistan’s high TB burden and limits of current prevention strategies, but support depended on robust evidence of **safety**, **effectiveness**, and **feasibility**. - Key barriers to vaccine acceptability identified were low perceived risk of TB, misinformation, stigma, sociocultural influences, and limited public awareness. - Critical enablers included community engagement, use of trusted healthcare providers, and clear, effective communication strategies. - Health system constraints flagged were workforce shortages, cold chain limitations, and financing challenges that could impede rollout. - Stakeholders prioritized household contacts of TB patients first, followed by adolescents and people living with HIV as target groups for early vaccination. - A phased implementation approach was broadly preferred, with gradual integration into existing health services rather than immediate universal rollout. - Authors conclude early stakeholder engagement, context-specific delivery planning, and strengthened health system capacity are essential for meaningful public health impact in Pakistan. - Ethical approvals were obtained from Aga Khan University (IRB reference # 2025-10755-32849) and Emory University (IRB reference # STUDY00003098); all participants gave informed consent. - Data are available on reasonable request to the authors. Funding was declared from the National Institutes of Health (1K01AI166093-01A1).
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=VDpYQW3avci4cq4eXGH9TpieJLaC1slFkKoU7K14j30-1788201291.4023204-1.2.1.1-ZnXN1zliloaGlLuWxpG9HqB9tQRL08rcqtcXNYFYTLyYSl3ACqIx07tEpXEsRqBk) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.08.26.26360963v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Stakeholder perspectives on the potential introduction of a novel tuberculosis vaccine for adolescents and adults in Pakistan: A qualitative study Zoyia Hassan, Zoya Zurez, Muhammed Saad, Nazia Ahsan, [ View ORCID Profile](http://orcid.org/0000-0001-8923-0301)Rebecca A Clark, Richard G White, Abdul Momin Kazi, [ View ORCID Profile](http://orcid.org/0000-0003-4728-2909)Kristin Nelson doi: https://doi.org/10.64898/2026.08.26.26360963 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Zoyia Hassan 1 Aga Khan University Hospital; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Zoyia%2BHassan%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Hassan%20Z&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AZoyia%2BHassan%2B) Zoya Zurez 1 Aga Khan University Hospital; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Zoya%2BZurez%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Zurez%20Z&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AZoya%2BZurez%2B) Muhammed Saad 1 Aga Khan University Hospital; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Muhammed%2BSaad%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Saad%20M&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMuhammed%2BSaad%2B) Nazia Ahsan 1 Aga Khan University Hospital; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Nazia%2BAhsan%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Ahsan%20N&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ANazia%2BAhsan%2B) Rebecca A Clark 2 London School of Hygiene and Tropical Medicine; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Rebecca%2BA%2BClark%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Clark%20RA&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ARebecca%2BA%2BClark%2B) * [ORCID record for Rebecca A Clark](http://orcid.org/0000-0001-8923-0301 "Open in new tab") Richard G White 3 London School of Hygiene & Tropical Medicine; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Richard%2B%2BG%2BWhite%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=White%20R&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ARichard%2B%2BG%2BWhite%2B) Abdul Momin Kazi 1 Aga Khan University Hospital; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Abdul%2B%2BMomin%2BKazi%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Kazi%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAbdul%2B%2BMomin%2BKazi%2B) Kristin Nelson 4 Emory University * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Kristin%2BNelson%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Nelson%20K&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AKristin%2BNelson%2B) * [ORCID record for Kristin Nelson](http://orcid.org/0000-0003-4728-2909 "Open in new tab") * For correspondence: knbratt@emory.edu * [Abstract](https://www.medrxiv.org/content/10.64898/2026.08.26.26360963v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1289139/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.08.26.26360963v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1289139/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.08.26.26360963v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1289139/1) * [Supplementary material](https://www.medrxiv.org/content/10.64898/2026.08.26.26360963v1.supplementary-material)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_data/node:1289139/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.08.26.26360963v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1289139/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.08.26.26360963v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1289139/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Background: Tuberculosis (TB) remains a major public health challenge globally, with Pakistan ranking among the highest TB burden countries worldwide. Although several novel TB vaccine candidates for adolescents and adults are advancing through late-stage clinical trials, little is known about how these vaccines may be introduced in high-burden settings such as Pakistan. Understanding stakeholder perspectives is crucial for informing early implementation planning and policy development. Methods: We conducted an exploratory qualitative study using semi-structured in-depth interviews with key stakeholders involved in TB control, immunization, clinical care, and health policy in Pakistan. Participants were purposively selected from national and provincial TB programs, Expanded Programme on Immunization (EPI), clinical settings, and academia. Interviews were conducted in English or Urdu, audio-recorded, transcribed verbatim, and analyzed using reflexive thematic analysis following the Braun and Clarke framework. A hybrid deductive-inductive coding approach was used. Results: Ten stakeholders participated including one whose interview also served as a pilot test of the interview guide. Participants expressed strong support for the introduction of a new TB vaccine, driven largely by Pakistan's high TB burden and the limitations of current prevention strategies. However, support was based on the availability of strong evidence regarding vaccine safety, effectiveness, and feasibility. Key barriers to vaccine acceptability included low perceived risk of TB, misinformation, stigma, sociocultural influences, and limited public awareness. Stakeholders emphasized community engagement, trusted healthcare providers, and effective communication as critical enablers. Health system challenges included workforce shortages, cold chain limitations, and financing constraints. Household contacts of TB patients were consistently identified as the priority group followed by adolescents and people living with HIV. A phased implementation strategy was broadly preferred followed by gradual integration into existing health services. Conclusion: Stakeholders in Pakistan broadly support new TB vaccines for adolescents and adults. Successful implementation will require addressing sociocultural barriers, strengthening health system capacity, and developing context-specific delivery and prioritization strategies. Early stakeholder engagement and implementation planning are essential for meaningful public health impact in Pakistan. ### Competing Interest Statement The authors have declared no competing interest. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Ethical approval was obtained from the institutional review boards of Aga Khan University (IRB reference #: 2025-10755-32849) and Emory University (IRB reference #: STUDY00003098). All participants provided informed consent prior to participation. Identifying information was removed from transcripts and data was stored in password protected files accessible only to the research team. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability All data produced in the present study are available upon reasonable request to the authors. ## Funder Information Declared National Institutes of Health, https://ror.org/01cwqze88, 1K01AI166093-01A1 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/). bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.08.26.26360963v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.08.27.26361488v1 "Acute Protein Responses Control SARS-CoV-2-specific Neurocognitive and General Post-Viral Sequelae")[Next ](https://www.medrxiv.org/content/10.64898/2026.08.26.26361436v1 "Prospective In-silico Simulation of the VESALIUS-CV Trial Using Biomedical Knowledge Graph and Real-World Data-Driven AI Modeling") Posted August 31, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.08.26.26360963v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/08/31/2026.08.26.26360963.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.08.26.26360963v1#p-5) [Supplementary Material ](https://www.medrxiv.org/content/10.64898/2026.08.26.26360963v1.supplementary-material) [ Data/Code](https://www.medrxiv.org/content/early/2026/08/31/2026.08.26.26360963.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Stakeholder perspectives on the potential introduction of a novel tuberculosis vaccine for adolescents and adults in Pakistan: A qualitative study Zoyia Hassan, Zoya Zurez, Muhammed Saad, Nazia Ahsan, Rebecca A Clark, Richard G White, Abdul Momin Kazi, Kristin Nelson medRxiv 2026.08.26.26360963; doi: https://doi.org/10.64898/2026.08.26.26360963 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.26.26360963v1%26text%3DStakeholder%2520perspectives%2520on%2520the%2520potential%2520introduction%2520of%2520a%2520novel%2520tuberculosis%2520vaccine%2520for%2520adolescents%2520and%2520adults%2520in%2520Pakistan%253A%2520A%2520qualitative%2520study "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.26.26360963v1%26t%3DStakeholder%2520perspectives%2520on%2520the%2520potential%2520introduction%2520of%2520a%2520novel%2520tuberculosis%2520vaccine%2520for%2520adolescents%2520and%2520adults%2520in%2520Pakistan%253A%2520A%2520qualitative%2520study "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.26.26360963v1%26title%3DStakeholder%2520perspectives%2520on%2520the%2520potential%2520introduction%2520of%2520a%2520novel%2520tuberculosis%2520vaccine%2520for%2520adolescents%2520and%2520adults%2520in%2520Pakistan%253A%2520A%2520qualitative%2520study%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.26.26360963v1%26title%3DStakeholder%2520perspectives%2520on%2520the%2520potential%2520introduction%2520of%2520a%2520novel%2520tuberculosis%2520vaccine%2520for%2520adolescents%2520and%2520adults%2520in%2520Pakistan%253A%2520A%2520qualitative%2520study "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") [ Get QR code](https://connect.medrxiv.org/qr/2026.08.26.26360963) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.64898/2026.08.26.26360963v1&count=horizontal&via=&text=Stakeholder%20perspectives%20on%20the%20potential%20introduction%20of%20a%20novel%20tuberculosis%20vaccine%20for%20adolescents%20and%20adults%20in%20Pakistan%3A%20A%20qualitative%20study&counturl=www.medrxiv.org/content/10.64898/2026.08.26.26360963v1 "Tweet This") ## Subject Area * [Public and Global Health ](https://www.medrxiv.org/collection/public-and-global-health) Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.medrxiv.org/content/early/recent) * [Addiction Medicine](https://www.medrxiv.org/collection/addiction-medicine) (613) * [Allergy and Immunology](https://www.medrxiv.org/collection/allergy-and-immunology) (894) * [Anesthesia](https://www.medrxiv.org/collection/anesthesia) (325) * [Cardiovascular Medicine](https://www.medrxiv.org/collection/cardiovascular-medicine) (4757) * [Dentistry and Oral Medicine](https://www.medrxiv.org/collection/dentistry-and-oral-medicine) (474) * [Dermatology](https://www.medrxiv.org/collection/dermatology) (406) * [Emergency Medicine](https://www.medrxiv.org/collection/emergency-medicine) (641) * [Endocrinology (including Diabetes Mellitus and Metabolic Disease)](https://www.medrxiv.org/collection/endocrinology-including-diabetes-mellitus-and-metabolic-disease) (1612) * [Epidemiology](https://www.medrxiv.org/collection/epidemiology) (15817) * [Forensic Medicine](https://www.medrxiv.org/collection/forensic-medicine) (32) * [Gastroenterology](https://www.medrxiv.org/collection/gastroenterology) (1194) * [Genetic and Genomic Medicine](https://www.medrxiv.org/collection/genetic-and-genomic-medicine) (6973) * [Geriatric Medicine](https://www.medrxiv.org/collection/geriatric-medicine) (727) * [Health Economics](https://www.medrxiv.org/collection/health-economics) (1055) * [Health Informatics](https://www.medrxiv.org/collection/health-informatics) (4968) * [Health Policy](https://www.medrxiv.org/collection/health-policy) (1423) * [Health Systems and Quality Improvement](https://www.medrxiv.org/collection/health-systems-and-quality-improvement) (1732) * [Hematology](https://www.medrxiv.org/collection/hematology) (579) * [HIV/AIDS](https://www.medrxiv.org/collection/hiv-aids) (1332) * [Infectious Diseases (except HIV/AIDS)](https://www.medrxiv.org/collection/infectious_diseases) (16235) * [Intensive Care and Critical Care Medicine](https://www.medrxiv.org/collection/intensive-care-and-critical-care-medicine) (1160) * [Medical Education](https://www.medrxiv.org/collection/medical-education) (661) * [Medical Ethics](https://www.medrxiv.org/collection/medical-ethics) (150) * [Nephrology](https://www.medrxiv.org/collection/nephrology) (718) * [Neurology](https://www.medrxiv.org/collection/neurology) (7174) * [Nursing](https://www.medrxiv.org/collection/nursing) (363) * [Nutrition](https://www.medrxiv.org/collection/nutrition) (1072) * [Obstetrics and Gynecology](https://www.medrxiv.org/collection/obstetrics-and-gynecology) (1228) * [Occupational and Environmental Health](https://www.medrxiv.org/collection/occupational-and-environmental-health) (999) * [Oncology](https://www.medrxiv.org/collection/oncology) (3566) * [Ophthalmology](https://www.medrxiv.org/collection/ophthalmology) (1034) * [Orthopedics](https://www.medrxiv.org/collection/orthopedics) (393) * [Otolaryngology](https://www.medr
## Related Clinical Research

- [Impact of a Person-Centered Care Intervention on HIV Treatment Reengagement in Zambia](https://medichelpline.com/clinical-feed/plos-medicine-2-effect-of-a-person-centered-care-intervention-on-return-and-sustained.md)
- [Urine-based Mtb antigen detection for childhood TB using an ultrasensitive ECL immunoassay](https://medichelpline.com/clinical-feed/medrxiv-16-the-accuracy-of-urine-based-mycobacterial-antigens-to-detect-childhood.md)
- [Natural products as adjuncts for non-tuberculous mycobacterial (NTM) infections: systematic review](https://medichelpline.com/clinical-feed/pubmed-42680847.md) (DOI: 10.1007/s10482-026-02416-5)
- [Person-centered care and reengagement after HIV treatment interruptions in Zambia: post-hoc analys](https://medichelpline.com/clinical-feed/pubmed-42679007.md) (DOI: 10.1371/journal.pmed.1005052)
- [Determinants of Favorable MDR-TB Treatment Outcomes in Zambia, 2018–2022](https://medichelpline.com/clinical-feed/plos-one-16-determinants-of-favorable-treatment-outcomes-in-multidrug-resistant.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.